Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Sep 25, 2018 3:26pm

110 Views

Post# 28687054

RE:RE:Volume

Don't get me wrong, nothing bad about and position of ATE at 0.36, lots of money to be made.
There is no guarantee this will go back down to 0.30 or 0.25
I just think there will be dips at times, if someone puts a bid at 0.30, In my opinion it will get filled sometime in the next 2 months. I also thing we will see 0.38+ in the next 2 months at times.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading